Beijing Konruns Pharmaceutical Co Ltd (SHG:603590) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Konruns Pharmaceutical Co Ltd (603590)
Beijing Konruns Pharmaceutical Co Ltd (SHG:603590) has a market capitalization of $696.42 Million (CN¥4.76 Billion) as of June 16, 2026. Listed on the SHG stock exchange, this China-based company holds position #10761 globally and #2996 in its home market, demonstrating a -3.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Konruns Pharmaceutical Co Ltd's stock price CN¥29.93 by its total outstanding shares 159010477 (159.01 Million). Review how much debt does Beijing Konruns Pharmaceutical Co Ltd carry to assess the company's total debt and financial obligations.
Beijing Konruns Pharmaceutical Co Ltd Market Cap History: 2018 to 2026
Beijing Konruns Pharmaceutical Co Ltd's market capitalization history from 2018 to 2026. Data shows change from $707.85 Million to $692.93 Million (-1.33% CAGR).
Beijing Konruns Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Konruns Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.01x
Beijing Konruns Pharmaceutical Co Ltd's market cap is 1.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.57x
Beijing Konruns Pharmaceutical Co Ltd's market cap is 5.57 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $707.85 Million | $973.16 Million | $263.93 Million | 0.73x | 2.68x |
| 2019 | $780.16 Million | $1.07 Billion | $266.08 Million | 0.73x | 2.93x |
| 2020 | $837.87 Million | $808.64 Million | $183.36 Million | 1.04x | 4.57x |
| 2021 | $743.22 Million | $809.78 Million | $147.99 Million | 0.92x | 5.02x |
| 2022 | $576.82 Million | $866.73 Million | $101.49 Million | 0.67x | 5.68x |
| 2023 | $886.05 Million | $920.01 Million | $150.45 Million | 0.96x | 5.89x |
| 2024 | $547.27 Million | $825.40 Million | $42.22 Million | 0.66x | 12.96x |
| 2025 | $924.91 Million | $915.12 Million | $165.97 Million | 1.01x | 5.57x |
Competitor Companies of 603590 by Market Capitalization
Companies near Beijing Konruns Pharmaceutical Co Ltd in the global market cap rankings as of June 16, 2026.
Key companies related to Beijing Konruns Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
Beijing Konruns Pharmaceutical Co Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Beijing Konruns Pharmaceutical Co Ltd's market cap moved from $707.85 Million to $ 692.93 Million, with a yearly change of -1.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥692.93 Million | -25.08% |
| 2025 | CN¥924.91 Million | +69.01% |
| 2024 | CN¥547.27 Million | -38.24% |
| 2023 | CN¥886.05 Million | +53.61% |
| 2022 | CN¥576.82 Million | -22.39% |
| 2021 | CN¥743.22 Million | -11.30% |
| 2020 | CN¥837.87 Million | +7.40% |
| 2019 | CN¥780.16 Million | +10.21% |
| 2018 | CN¥707.85 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of Beijing Konruns Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $696.42 Million USD |
| MoneyControl | $696.42 Million USD |
| MarketWatch | $696.42 Million USD |
| marketcap.company | $696.42 Million USD |
| Reuters | $696.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more